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Abstract 
Background: Hydroxyurea (HU) is underutilized in children with sickle cell disease (SCD) because caregivers fre-
quently decline HU when it is offered. This study explores what impacts this decision.
Results: Caregivers of children with clinically severe SCD whose children were offered HU previously were inter-
viewed. We used a qualitative analytical approach to analyze their telephone interview transcripts. Caregivers who 
chose HU (n = 9) reported their children had severe SCD, sought detailed information about HU, and accepted HU as 
a preventative therapy. In contrast, caregivers who did not choose HU (n = 10) did not perceive their children as hav-
ing severe SCD and did not question their child’s provider about HU.
Conclusions: This study identifies specific areas that providers should address to when they discuss HU with families 
so that they can make informed decisions. Our study also uncovered factors that are important to consider when 
designing future interventions to improve hydroxyurea acceptance and when developing decision-aid tools to assist 
caregivers of children with SCD who are considering disease modifying therapies.
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Background
Sickle cell disease (SCD) is an inherited red blood cell 
disorder that leads to early morbidity and mortality 
[1, 2]. Hydroxyurea (HU) is the only available disease-
modifying medication for patients with SCD [3]. Clini-
cal trials show that HU decreases vaso-occlusive pain 
(VOC), acute chest syndromes (ACS), hospitalizations, 
and transfusions in both pediatric and adult patients [4, 
5], and current guidelines are to offer HU therapy to all 
pediatric patients with Hemoglobin SS and Sβ0 SCD to 
reduce and prevent SCD complications [6].
HU is underutilized in clinical practice, and this 
results in worse clinical outcomes in pediatric patients 
with SCD. A major barrier to prescribing HU therapy is 
that 20 % of patients do not accept HU as a therapeutic 
option when it is offered [7]. Surveyed adult hematolo-
gists believe that this is because patients are fearful of 
side effects [8], whereas adult patients suggest that this is 
because patients lack knowledge about HU therapy and 
have unrealistic expectations about the time to effect 
with HU therapy [9]. For pediatric patients with SCD, 
caregivers are the primary decision makers but little is 
known about the factors that influence their decision 
about HU. Findings from caregiver surveys suggest that 
caregivers are concerned about HU’s side effects but also 
may not identify their child as sufficiently symptomatic 
to warrant HU therapy [10]. However, in-depth studies of 
caregivers that may identify significant, but unrecognized 
caregiver barriers do not exist. Fully understanding the 
caregiver perspective may help clinicians provide better 
education, counseling, and expectations to families about 
HU so that caregivers can make informed decisions for 
their children. It may also impact the design of future 
interventions to improve HU acceptance and decision-
aid tools to assist caregivers who are considering other 
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disease modifying therapies for SCD, such as chronic 
transfusion therapy and stem cell transplant. In this study 
we aim to explore what impacts caregivers’ decision to 
choose HU or not choose HU therapy for their children 
with SCD.
Methods
Participant identification
This study was approved by the University of Pittsburgh 
Institutional Review Board. The pediatric SCD team at 
Children’s Hospital of Pittsburgh (CHP) identified pedi-
atric patients who were offered HU therapy for clinically 
severe SCD prior to March 2012. Caregivers were eligi-
ble to participate if they were ≥18 years of age and their 
child’s medical record confirmed that a SCD provider 
had offered HU at least once prior to enrollment. We 
mailed prospective caregivers recruitment letters that 
stated the purpose of the study. All caregivers who con-
tacted the research team after receiving the letter were 
interviewed. We then attempted to contact the remaining 
prospective caregivers sequentially until thematic satura-
tion was achieved. Caregivers received a $20 gift card for 
participating in this study.
Qualitative interviews
The qualitative interviews followed a semi-structured 
interview guide. (Fig. 1) The interview guide was multi-
dimensional, allowing the interviewer to explore differ-
ent topical pathways, depending on how respondents 
answered prior questions. The specific categories that 
were chosen were based on a literature review of both 
HU and medical decision making [7–9, 11]. The initial 
interview guide was pilot tested on volunteers without 
SCD and the study’s qualitative expert (SZ) and then 
adjusted to improve the clarity and flow of the questions. 
The interviewer (SC) conducted all of the interviews over 
the telephone from March to October 2012. SZ trained 
SC to listen carefully to each interviewee’s responses to 
guide the interview spontaneously, avoid repetition, and 
probe interesting comments to investigate how caregivers 
made their decision to choose or not choose HU therapy 
when their child’s provider offered it. At the end of the 
interview, caregivers completed a short, verbal, demo-
graphic survey. A medical transcriptionist transcribed 
the digitally recorded interviews verbatim for analysis. 
SC reviewed these transcripts prior to the analysis for 
transcription accuracy.
Codebook construction
Two trained coders (SC and DR) read the transcripts 
iteratively to develop a qualitative codebook of themes, 
using the qualitative editing style developed by Miller 
and Crabtree [12]. All transcripts were double coded 
and the coders met regularly to resolve any coding 
discrepancies.
Medical record review
We used a standardized data collection form to record 
patients’ demographic information and the provider-doc-
umented indication for HU therapy within the medical 
record. We used descriptive statistics to describe demo-
graphic data.
Results
We identified 52 patients with SCD at CHP who were 
offered HU for clinically severe SCD before March 2012. 
Nineteen caregivers of 16 patients completed the inter-
view. Two caregivers contacted the research team after 
receiving the recruitment letter and then we consecu-
tively contacted the remaining caregivers (n  =  17) by 
telephone until thematic saturation was achieved. Each 
caregiver we contacted agreed to participate in the study. 
Approximately half (n  =  9) of the interviewed caregiv-
ers chose HU for their children with SCD (Table 1). The 
interviews lasted 18–54 min in duration (median 29 min, 
and mean 32 min).
During the iterative review of the transcripts, we iden-
tified common themes. Caregivers shared similar com-
ments and views about how SCD’s impacts their daily 
life and fears that they had about initiating HU therapy. 
There were other themes where the two caregiver groups 
had more contrasting comments and views (i.e. car-
egivers’ SCD knowledge, caregivers’ perception of their 
child’s disease severity, caregivers’ interactions with their 
medical team, and experiences with HU).
SCD’s impacts daily life
Most caregivers expressed difficulty living and coping 
with having a child with SCD. Many commented that 
SCD can be unpredictable and sometimes unrelenting. 
“Well there is never any rhyme or reason with sickle cell. 
We learned that over the years.” Others shared that hav-
ing a child with SCD significantly affected the entire fam-
ily because it frequently interrupted their familys’ plans, 
careers, and even their ability to make a living. One 
stated, “Oh, (the pain episodes) were overwhelming with 
dealing with his pain, and I have two other kids. So, it was 
really overwhelming, plus work. Like trying to get the 
strength down and you don’t know where you are going 
to get the strength from. But it works. I’ve prayed about 
it and prayed about it and I’ve prayed about it and that 
helps me get through it more than anything.” Caregiv-
ers admitted that their children had become emotionally 
upset because of their SCD, especially when the disease 
limited their activities or resulted in an emergency room 
visit or hospitalization.
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Introduction Script:
Thank you for agreeing to speak with me today about having a child with sickle cell disease. The interview should take about 45-60 minutes to 
complete. Please remember that everything you share with me will be kept strictly confidential. None of your information or information you 
share about your child will be shared to anyone outside of this study. Please know that there are no right or wrong answers to these questions, I 
am only interested in your opinions. If you find any of these topics difficult please let me know. If you wish to decline to answer, you may do so, 
and you do not have to give an explanation for this. If you need to take a break at any time, please let me know. If you have any questions, please 
let me know.  If you have questions regarding sickle cell disease or hydroxyurea, I will try and answer these at the end of the interview. Before I 
begin, do I have your permission to audio-record our conversation? Do you have any questions before we begin the interview?  (START AUDIO 
RECORDER) This is interview (study ID#) on (date) and he/she understands that this is interview is being recorded.  Is this correct?
Health Status -Tell me about your child’s health and what it is like having a child with sickle cell disease-What is your day-to-day life like dealing with sickle cell?
-Are there other kids at home?
-Do you have someone to help you take care of your child?
-Do you have someone to help you make decisions about your child?
-Has your child had any complications from his or her sickle cell disease?
-Tell me what happened with that?
-What was it like to be in the hospital?
-Do you know any adults with sickle cell disease?  If not, do you know anything about adults with sickle 
cell disease?
-Can you tell me what you expect your child’s life to be like as an adult? 
Autonomy -Can you tell me how you make decisions about your child’s care?
-What about decisions about your child’s medications?
Medications and 
Therapies
-What medications or therapies does your child take for his or her sickle cell disease? 
-How can you tell if these work?
-Do you use any other non-medical therapies to treat your child’s SCD?
-Do you think that these therapies work? 
-Are there any other suggestions your child’s health care professionals have told you about to help with 
your child’s sickle cell disease.
-How about your family or friends?
Hydroxyurea 
Acceptance
I’m now going to ask you some questions about HU.
-Tell me about what you know about HU.  Where did you learn about this?
-Just to confirm, is your child currently taking HU?
-If yes: Tell me what made you decide to start having your child take HU?
-Was there anything you were concerned about when your child started HU?
-Tell me about what it is like now that your child is on HU.
-Have the doctors ever told your child to stop HU? Why?
-Is there anything that would make you stop having your child take HU?
-If no: Tell me what made you decide to not have your child take HU.
-Is there anything that would change feelings about HU therapy?
Medication 
Adherence
We are very interested in patients taking medications.  
-Tell me about your child and taking medication.
-How do you remember to have your child take his or her medications?
-Taking medications regularly is difficult.  Does your child ever miss doses of his or her medications?  
-Is there anything doctors could do to help patients take their medications?
-In other diseases (such as TB), watching someone take a medication has been shown to help patients 
remember to take their medications.  Do you think this would work? 
-Some doctors don’t offer medications to patients because they are concerned that patients won’t get the 
proper follow up or take the medications, how do you feel about this?
Trust -Tell me about your child’s doctor.
-Would you recommend your child’s doctor to another person?
-Why or why not?
-Do you think your child’s doctor cares about your child?
-What does your child’s doctor do to let you know he or she cares?  
Coping -Are there times when you get upset about your child having sickle cell disease?  -Can you share what you do when this happens?
Perception of Child I now want to talk about what you think your child understands about his or her health.  I realize it may be 
difficult to know what your child is thinking, however, I would like to ask you some questions about what 
you think your child thinks and feels.  
-Tell me what your child understands about having sickle cell disease.  
-Are there times when your child gets upset because of his or her sickle cell disease?
-Can you tell me what he or she does when this happens?
-Tell me what your child does when there are decisions to be made about his or her health.
Conclusion -What advice would you give physicians about caring for patients with sickle cell disease?
-How would you recommend physicians speak to patients and caregivers about making decisions about 
sickle cell disease?
Fig. 1 The semi-structured interview guide
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Fears about initiating HU therapy
Commonly, caregivers stated they were fearful about 
starting HU therapy, even if they ultimately decided to 
choose HU. They expressed anxiety and difficulty under-
standing why a child with SCD would be offered HU, 
especially when they learned it was a chemotherapy med-
ication. “She (the nurse practitioner) was saying that they 
use it (HU) on chemo patients. My thing was like, ‘Well 
it’s not going to cause him to get cancer or anything like 
that?’ And she was like, ‘No, it is not that type of medica-
tion,’ and I was like, ‘Oh, okay.’ Because when you hear… 
when she was explaining to me the medication, when she 
was saying that this is what the chemo patients use, and I 
was like well, my first instinct was like, do we have cancer 
and you’re not telling me? That was my first instinct.”
Caregivers’ SCD knowledge
When caregivers were asked what they felt was impor-
tant for a physician to know when caring for patients with 
SCD, all caregivers commented that providers should 
give as much information to parents as possible to bet-
ter prepare them to deal with their children’s health. Both 
groups indicated that they felt they would benefit from 
having more information about SCD and some suggested 
an education program for parents and patients could be 
beneficial.
Both caregiver groups had caregivers who achieved a 
variety of different education levels (Table 1). Responses 
from caregivers who chose HU suggested that they had 
a better understanding of SCD and that they specifically 
sought more detailed and in-depth information about 
SCD and HU. “I’m a parent. They (the providers) just 
gave me a pamphlet. The pamphlet doesn’t tell you eve-
rything… there’s more research behind the pamphlet… I 
think that’s very important to a parent to give their child 
medication.” In contrast, many caregivers who did not 
choose HU admitted during the interview that they had 
a poor understanding of SCD and what to expect in the 
future. “I don’t even know what’s going to happen when 
she turns 18 or becomes an adult. Like I don’t know how 
this runs from now to then.”
Caregiver’s perception of SCD severity
All of the caregivers in the study had a child who had 
experienced a severe SCD-related complication, such as 
ACS or VOC (Table  1). Caregivers who did not choose 
HU, however, indicated that they would only consider 
HU if their child had more severe complications in the 
future. “I see her to be severe, (to have severe SCD), but I 
don’t see her to be as severe as some of the cases that I’ve 
seen.” A few caregivers in this group also tended to focus 
on their child’s short-term health. “More than likely, 
we’re just concerned about keeping him healthy and stuff 
for now.” In comparison, caregivers who chose HU iden-
tified medications, such as HU, as a way to prevent com-
plications and to extend their child’s life. “They say that 
your life expectancy (with SCD) is up, like, when you are 
42  years old. I know people who live way past 42  years 
old. So, there are other ways around it. You have to take 
care of yourself. You have to take your medication (HU).”
Caregivers’ interaction with the medical team
All caregivers in this study identified themselves as a 
decision maker for their child and stated that they were 
responsible for their child’s health and medications. 
When asked if they trusted their child’s hematologist, 
Table 1 Characteristics of  children with  SCD and  their 
interviewed caregivers
Variables Did not  
choose HU
Chose HU
Patients n = 8 n = 8
 Patient age (years)
  Median 13 8
  Range 5–18 2–17
 Gender (n)
  Female 4 3
 Genotype (n)
  SS 5 8
  SC 3 0
 Indication for HU therapy (n)
  ACS only 1 2
  Frequent VOC only 3 1
  VOC and ACS 4 5
Caregivers n = 10 n = 9
 Caregiver age (years)
  Median 35.5 32
  Range 26–67 24–45
 Caregiver gender (n)
  Female 8 7
 Caregiver relationship to patient (n)
  Biological parent 6 7
  Biological grandparent 1 2
  Other (adoptive parent or family 
friend)
3 0
 Caregiver education (n)
  <12th grade 0 0
  High school 1 1
  Associates degree or finishing 
degree
4 5
  Bachelors 4 2
  Graduate degree 0 1
  Did not disclose 3 0
 Caregiver employed (n)
  Yes 5 8
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most spoke positively about their relationship with their 
child’s physician and consistently stated they would rec-
ommend their child’s SCD team to other caregivers.
Although caregivers sought guidance from their fami-
lies and their child’s health providers, caregivers who 
chose HU felt the need to be proactive and ask their 
child’s providers questions. “They (the doctors) are easy 
to talk to, which is good, but also as a parent, you have 
to ask questions. You know, if you don’t understand any-
thing. You know, a closed mouth doesn’t get fed. So if 
you don’t ask, they’re not going to answer it for you.” In 
contrast, caregivers who did not choose HU depended 
on their child’s physician to direct the medical decision-
making process for their child. “I don’t second guess 
anything because I know it’s best for his care. If they 
(the doctors) say to do something, then we do it.” Fur-
thermore, some of these caregivers reported that when 
their physician offered HU to them as a potential therapy, 
they did not engage their child’s physician in a discus-
sion about HU, even when they were fearful about what 
they had read or heard from other sources. “I was curi-
ous (about HU) and I came home and I got on the com-
puter and there were so many things about it that kind 
of frightened me… There was just a lot and I’m thinking, 
‘Wow, what type of medication is this?’” But when asked 
in follow up questioning if this caregiver had asked her 
provider about what she had read, she paused and said, 
“No, I didn’t.”
Experiences with HU
Two caregivers who did not chose HU revealed during 
their interviews that their children had previously tried 
HU but discontinued it. They both admitted that their 
children took HU for less than 6  months and missed 
doses. Ultimately, they stated that they decided to dis-
continue HU because their children continued to have 
VOC, experienced side effects, and did not seem to ben-
efit from HU. “If her (the patient’s) stomach was hurting 
too much, we would stop (HU) for a couple of days and 
then we’d say, ‘Ok let’s try it again’ and that type of deal. 
But it really was bad. It (HU) really made her stomach 
hurt a lot. She really did not enjoy taking it whatsoever.” 
One of these caregivers went on to state that her child’s 
experience with HU was so terrible that she would not 
consider HU therapy in the future, even if their child’s 
SCD-related symptoms were to worsen.
In contrast, we asked caregivers who chose HU to share 
what they would tell another caregiver of a child with 
SCD about HU. They consistently stated that they would 
recommend HU because their own children had fewer 
SCD-related complications and more energy with HU. 
“I’d strongly recommend that they give it (HU) a chance 
and see what it can do because I’m sure it doesn’t work 
the same in everybody, but you never know until you try.” 
A few of these caregivers also expressed that they would 
be reluctant to stop HU therapy under any circumstances 
because their child was doing so well.
Discussion
HU is an efficacious medication for pediatric patients 
with SCD, yet many caregivers do not choose HU for 
their child when it is offered [7]. The most recent ver-
sion of the National Heart, Lung and Blood Institute 
Guidelines recommends that providers “offer HU” to all 
children with severe SCD to encourage shared decision 
making about HU [6]. The caregiver perspective, how-
ever, is largely unknown, and pediatric hematologists and 
nurses may find this information useful to better counsel 
caregivers about HU and to improve HU utilization.
It is important to note that all caregivers reported that 
SCD negatively affects their daily lives. These comments 
are striking and highlight the need for more widespread 
use of efficacious therapies, such as HU, to mitigate SCD 
complications. We also found that even caregivers who 
choose HU for their children reported being fearful about 
initiating HU. To overcome this fear, we suggest that pro-
viders initiate early and ongoing discussions about HU 
with families. This gives families time to gather informa-
tion about HU and allows providers the opportunity to 
address parental fears before severe SCD complications 
begin to manifest and persist in patients’ daily lives.
Also, our interviews suggest that knowledge among 
caregivers of children with SCD is quite variable. It is 
clear, however, that caregivers want more information 
about SCD, its complications, and HU therapy so that 
they can make informed decisions. We suggest that the 
first step is to formally assess caregivers’ health literacy 
since this is associated with health outcomes [13, 14] and 
then to assess caregivers’ SCD knowledge, potentially 
using the validated Sickle Cell Knowledge Questionnaire 
[15]. Once health literacy and SCD knowledge gaps are 
identified, targeted interventions such as group educa-
tion sessions, which have been shown to successfully 
improve knowledge for patients with chronic diseases, 
could be used to inform caregivers [16].
All of the caregivers in this study had children who had 
experienced a severe SCD complication, but similar to 
Oyeku et  al. [10], many caregivers who did not choose 
HU did not perceive that their child had severe enough 
SCD to warrant HU therapy. Some possible explana-
tions for this are that caregivers may not understand that 
frequent VOC and ACS are severe complications, have 
other children with SCD to use as a comparison, or want 
to acknowledge that their child has severe SCD.
It is important to note that a few caregivers on 
this study who did not choose HU had children with 
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Hemoglobin SC disease. Although patients with Hemo-
globin SC SCD typically have a milder clinical phenotype 
compared to patients with Hemoglobin SS SCD, patients 
with Hemolglobin SC can still have severe disease mani-
festations and for these patients, many providers will 
offer HU since small studies show it can be beneficial 
[17]. Thus, we suggest that providers routinely update 
families each time their child has a severe SCD-related 
complication so they can accurately assess their child’s 
risk and disease severity, since as many as half of parents 
will rate that their child has mild SCD [18].
In contrast to prior studies [9, 10], caregivers in our 
study did not consistently state that HU side effects were 
an important factor in their decision to choose or not 
choose HU. The caregivers of the patients that discon-
tinued HU therapy did comment that side effects were 
a problem. Our results and other surveys suggest that 
caregivers may still have concerns and misconceptions 
about HU therapy and its potential to cause malignancy 
[11]. To overcome these potential barriers, we suggest 
that clinicians anticipate these questions and specifically 
address these concerns in their early discussions about 
HU with families. For instance, physicians could provide 
all families with the same information on HU, such as the 
indication for wanting to start this therapy, the length 
of time to expect before HU may begin to reduce symp-
toms, the importance of regular HU adherence, the theo-
retical malignancy risk, and the common side effects they 
may encounter so that caregivers have fewer unanswered 
questions and unrealistic expectations about HU.
Our study has a few limitations. First, inherent in the 
qualitative study design, the data is limited to the infor-
mation that subjects chose to share during the inter-
view. To facilitate participant sharing, we did reassure 
caregivers of their privacy and anonymity prior to their 
interview. We acknowledge though that the first author 
[SC] created the interview guide, completed the inter-
views, and was a hematology fellow who intermittently 
cared for some of the patients around the time that the 
interviews were completed and this may have limited 
the information that some caregivers chose to disclose. 
Second, three of the interviewed caregivers were from 
the same family. Although it is reasonable to expect that 
caregivers from the same family would report similar 
answers in the interview, each caregiver’s interview was 
conducted independently and privately so that caregiv-
ers could openly share their opinions even if they were 
different from other caregivers within the same family. 
To prevent over-representation of one family’s opinion 
in our results, we continued to interview caregivers of 
independent patients sequentially until thematic satu-
ration was achieved. Lastly, although CHP is a tertiary 
children’s hospital with similar resources and a similar 
patient population to other pediatric SCD Comprehen-
sive Programs in the United States, all of the caregivers 
we interviewed had children who were followed at a sin-
gle institution and may limit the generalizability of our 
results.
Conclusions
This study is unique as it provides an in-depth perspec-
tive about caregivers’ decision to have their children 
take or not take HU. Our results suggest areas where 
interventions could be developed (e.g. caregivers’ SCD 
knowledge or caregivers’ interactions with the medical 
team) and tested to determine if they result in increased 
HU use and improved outcomes in pediatric patients 
with SCD. These results could also be used when devel-
oping decision aid tools so that all the factors identi-
fied by caregivers as potential barriers are addressed 
and caregivers feel empowered and informed to make a 
decision about HU and other disease modifying thera-
pies [19]. Finally, although most pediatric hematolo-
gists and published guidelines support that HU therapy 
be offered to all pediatric patients with Hemoglobin-SS 
and Sβ0 SCD, a consensus that HU is a standard-of-care 
treatment for children with SCD may provide the neces-
sary reassurance to caregivers that HU is effective and 
safe and may result in more caregivers choosing HU for 
their children.
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